When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

J Thromb Haemost. 2016 Mar;14(3):623-7. doi: 10.1111/jth.13227. Epub 2016 Feb 17.
No abstract available

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Administration, Oral
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Antidotes / adverse effects
  • Antidotes / pharmacokinetics
  • Antidotes / therapeutic use*
  • Arginine / analogs & derivatives
  • Arginine / therapeutic use
  • Blood Coagulation / drug effects*
  • Coagulants / adverse effects
  • Coagulants / pharmacokinetics
  • Coagulants / therapeutic use*
  • Factor Xa / therapeutic use
  • Hemorrhage / chemically induced
  • Hemorrhage / drug therapy*
  • Humans
  • Piperazines / therapeutic use
  • Recombinant Proteins / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antidotes
  • Coagulants
  • PRT064445
  • Piperazines
  • Recombinant Proteins
  • Arginine
  • idarucizumab
  • Factor Xa
  • PER977